Aliases & Classifications for Coronary Heart Disease 1

MalaCards integrated aliases for Coronary Heart Disease 1:

Name: Coronary Heart Disease 1 53 28
Coronary Heart Disease 53 72 28 51 69 59
Coronary Heart Disease, Susceptibility to, 1 53 69
Coronary Heart Disease, Susceptibility to 53
Coronary Arteriosclerosis 69
Coronary Artery Disease 69
Chds1 53
Chd 44

Classifications:



External Ids:

OMIM 53 607339

Summaries for Coronary Heart Disease 1

PubMed Health : 59
About coronary heart disease: Coronary heart disease (CHD) is a disease in which a waxy substance called plaque (plak) builds up inside the coronary arteries. These arteries supply oxygen-rich blood to your heart muscle.When plaque builds up in the arteries, the condition is called atherosclerosis (ATH-er-o-skler-O-sis). The buildup of plaque occurs over many years.

MalaCards based summary : Coronary Heart Disease 1, also known as coronary heart disease, is related to hypoalphalipoproteinemia, primary and heart disease, and has symptoms including equilibration disorder, substernal pain and tremor. An important gene associated with Coronary Heart Disease 1 is CX3CR1 (C-X3-C Motif Chemokine Receptor 1), and among its related pathways/superpathways are Metabolism of water-soluble vitamins and cofactors and Selenium Micronutrient Network. The drugs Menthol and Angiotensin II have been mentioned in the context of this disorder. Affiliated tissues include heart and liver, and related phenotypes are Decreased free cholesterol and Increased LDL uptake

Wikipedia : 72 Coronary artery disease (CAD), also known as ischemic heart disease (IHD), refers to a group of diseases... more...

Description from OMIM: 607339

Related Diseases for Coronary Heart Disease 1

Diseases in the Coronary Heart Disease 1 family:

Coronary Heart Disease 3 Coronary Heart Disease 2
Coronary Heart Disease 4 Coronary Heart Disease 5
Coronary Heart Disease 7 Coronary Heart Disease 8
Coronary Heart Disease 9 Coronary Heart Disease 6

Diseases related to Coronary Heart Disease 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 104)
# Related Disease Score Top Affiliating Genes
1 hypoalphalipoproteinemia, primary 31.7 APOA1 APOB APOC3 CETP LPL
2 heart disease 31.4 ACE ADRB1 APOB APOE CRP HMGCR
3 coronary artery anomaly 31.1 ACE ADRB1 APOA1 APOB APOC3 APOE
4 arteries, anomalies of 28.9 ACE APOA1 APOB APOE CETP COG2
5 coronary heart disease 2 11.4
6 coronary heart disease 4 11.4
7 coronary heart disease 5 11.4
8 coronary heart disease 3 11.3
9 coronary heart disease 7 11.3
10 coronary heart disease 8 11.3
11 coronary heart disease 9 11.3
12 coronary heart disease 6 11.3
13 total anomalous pulmonary venous return 1 11.0
14 abdominal obesity-metabolic syndrome 1 11.0
15 prinzmetal's variant angina 11.0
16 congenitally corrected transposition of the great arteries 10.9
17 malignant otitis externa 10.5 CRP INS
18 xanthoma disseminatum 10.5 APOB APOE
19 hypercholesterolemia, autosomal dominant, type b 10.5 APOB APOE
20 moderate and severe traumatic brain injury 10.5 ACE APOE
21 fetal macrosomia 10.5 APOA1 APOB INS
22 hepatic lipase deficiency 10.4 APOA1 APOE LPL
23 defective apolipoprotein b-100 10.4 APOB APOE HMGCR
24 hyperlipoproteinemia, type v 10.4 APOE INS LPL
25 leukodystrophy, hypomyelinating, 3 10.4 APOA1 APOB APOE
26 hypobetalipoproteinemia, familial, 1 10.4 APOA1 APOB APOE
27 systolic heart failure 10.4 ACE ADRB1 CRP
28 familial lcat deficiency 10.4 APOA1 APOE
29 marek disease 10.4 ACE HMGCR
30 peripheral artery disease 10.4 ACE APOB CRP
31 cerebral atherosclerosis 10.4 ACE APOA1 APOE
32 aortic valve disease 1 10.4 ACE APOB CRP
33 generalized atherosclerosis 10.4 ACE APOE CRP
34 abdominal obesity-metabolic syndrome quantitative trait locus 2 10.4 CRP INS
35 hemorrhage, intracerebral 10.4 ACE APOE HMGCR
36 hyperuricemia 10.4 APOB CRP INS
37 uremia 10.3 APOC3 CRP INS LPL
38 morbid obesity 10.3 CRP INS LPL
39 homozygous familial hypercholesterolemia 10.3 APOB APOE HMGCR LPL
40 hypolipoproteinemia 10.3 APOA1 APOB APOE LPL
41 xanthomatosis 10.3 APOB APOE HMGCR LPL
42 prediabetes syndrome 10.3 APOB COG2 CRP INS
43 carotid stenosis 10.3 ACE APOE CRP
44 overnutrition 10.3 APOB COG2 CRP INS
45 microvascular complications of diabetes 5 10.3 ACE INS PON1
46 peripheral vascular disease 10.3 ACE APOA1 APOB CRP
47 aortic aneurysm, familial abdominal, 1 10.3 ACE APOE CRP
48 tangier disease 10.3 APOA1 APOB APOE CETP
49 mediastinitis 10.3 CRP INS
50 vascular dementia 10.3 ACE APOE PON1

Graphical network of the top 20 diseases related to Coronary Heart Disease 1:



Diseases related to Coronary Heart Disease 1

Symptoms & Phenotypes for Coronary Heart Disease 1

Clinical features from OMIM:

607339

UMLS symptoms related to Coronary Heart Disease 1:


equilibration disorder, substernal pain, tremor, edema, chest pain, angina pectoris

GenomeRNAi Phenotypes related to Coronary Heart Disease 1 according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased free cholesterol GR00340-A-2 9.5 HMGCR LPL APOA1 APOB APOC3 APOE
2 Increased LDL uptake GR00340-A-1 8.8 LPL APOA1 APOE

MGI Mouse Phenotypes related to Coronary Heart Disease 1:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.85 APOB APOE CRP CX3CR1 INS LPL
2 homeostasis/metabolism MP:0005376 9.73 APOA1 APOB APOE COG2 CRP CX3CR1
3 liver/biliary system MP:0005370 9.17 APOB APOE HMGCR INS LPL ACE

Drugs & Therapeutics for Coronary Heart Disease 1

PubMedHealth treatment related to Coronary Heart Disease 1: 59

Treatments for coronary heart disease (CHD) include lifestyle changes, medicines, and medical procedures. Treatment goals may include:Relieving symptoms.Reducing risk factors in an effort to slow, stop, or reverse the buildup of plaque.Lowering the risk of blood clots forming. (Blood clots can cause a heart attack.)Widening or bypassing clogged arteries.Preventing complications of CHD.

Drugs for Coronary Heart Disease 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1045)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Menthol Approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 2216-51-5 16666
2
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
3
Olmesartan Approved, Investigational Phase 4,Phase 2 144689-24-7, 144689-63-4 158781 130881
4
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 159351-69-6 6442177
5
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
6
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 53123-88-9 46835353 6436030 5284616
7
Clopidogrel Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 120202-66-6, 113665-84-2 60606
8
Ticagrelor Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 274693-27-5 9871419
9
Ticlopidine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 55142-85-3 5472
10
Cilostazol Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 73963-72-1 2754
11
Heparin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 9005-49-6 46507594 772
12
Tirofiban Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 144494-65-5 60947
13
Chlorhexidine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 55-56-1 2713 9552079
14
Aspirin Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 50-78-2 2244
15
Chromium Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 7440-47-3 27668
16
Simvastatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 79902-63-9 54454
17
Trimetazidine Approved, Investigational Phase 4,Not Applicable 5011-34-7
18
Insulin Glargine Approved Phase 4,Phase 3 160337-95-1
19
Metformin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 657-24-9 4091 14219
20
Zinc Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7440-66-6 32051 23994
21
Amlodipine Approved Phase 4,Phase 3,Phase 2,Not Applicable 88150-42-9 2162
22
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 111025-46-8 4829
23
Acarbose Approved, Investigational Phase 4,Phase 3,Not Applicable 56180-94-0 441184
24
Fluvastatin Approved Phase 4,Phase 3,Phase 2,Not Applicable 93957-54-1 1548972
25
Ranolazine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 95635-55-5, 142387-99-3 56959
26
Rivaroxaban Approved Phase 4,Phase 3,Phase 2 366789-02-8
27
Warfarin Approved Phase 4,Phase 2,Phase 3,Not Applicable 81-81-2 54678486 6691
28
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 33069-62-4 36314
29
Pitavastatin Approved Phase 4,Phase 3,Not Applicable 147511-69-1, 147526-32-7 5282452 6366718
30
Rosiglitazone Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 122320-73-4 77999
31
Ezetimibe Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 163222-33-1 150311
32
Lovastatin Approved, Investigational Phase 4,Phase 2,Phase 3 75330-75-5 53232
33
Carvedilol Approved, Investigational Phase 4,Phase 3,Phase 1,Not Applicable 72956-09-3 2585
34
Bivalirudin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 128270-60-0 16129704
35
Adenosine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-61-7 60961
36
Dipyridamole Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-32-2 3108
37
Regadenoson Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 313348-27-5 219024
38
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 1994-09-7, 94-09-7 2337
39
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 76631-46-4, 113775-47-6 5311068 56032 68602
40
Etomidate Approved Phase 4 33125-97-2 667484 36339
41
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570
42
Ropivacaine Approved Phase 4,Not Applicable 84057-95-4 175805 71273
43
Sevoflurane Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 28523-86-6 5206
44
Sufentanil Approved, Investigational Phase 4,Not Applicable 56030-54-7 41693
45
Nicorandil Approved, Investigational Phase 4,Phase 3,Not Applicable 65141-46-0 47528
46
Ethanol Approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 64-17-5 702
47
Thrombin Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable
48
Vorapaxar Approved Phase 4,Phase 3,Phase 2,Phase 1 618385-01-6
49
Metoprolol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 51384-51-1, 37350-58-6 4171
50
Omeprazole Approved, Investigational, Vet_approved Phase 4,Phase 3 73590-58-6 4594

Interventional clinical trials:

(show top 50) (show all 7299)

# Name Status NCT ID Phase Drugs
1 Danshen Dropping Pill for Coronary Heart Disease Heart and Artery Structure and Function Unknown status NCT01825759 Phase 4 danshen dripping pill
2 Endothelial Dysfunction in Subjects With History of Premature Coronary Artery Disease Unknown status NCT00917527 Phase 4 Atorvastatin
3 Clinical Evaluation of Magnetic Resonance Imaging in Coronary Heart Disease-2 Unknown status NCT01664858 Phase 4
4 Rosuvastatin Effect on Reducing Coronary Atherosclerosis Plaques Volume Unknown status NCT01382277 Phase 4 Rosuvastatin
5 Efficacy Study of Olmesartan Medoxomil on Coronary Atherosclerosis and Epicardial Adipose Tissue(EAT) Unknown status NCT02360956 Phase 4 Olmesartan medoxomil tablets;Antihypertensive medication (per doctor suggestion)
6 Study to Investigate the Effect of Heart Rate Reduction With Ivabradine on Vascular Elastic Properties and Endothelial Function in Patients With Stable Coronary Heart Disease Unknown status NCT01768585 Phase 4 Ivabradine;Placebo
7 The Beneficial Role of Percutaneous Coronary Intervention Over Optimal Medical Therapy in Elderly Patients With Coronary Artery Disease Unknown status NCT01508663 Phase 4 ARB, CCB, ACE-inhibitor, statin, Nitrate, Antiplate etc.
8 Safety and Efficacy of Low-dose Ticagrelor in Chinese Patients With Stable Coronary Artery Disease Unknown status NCT02514642 Phase 4 low-dose ticagrelor;Clopidogrel
9 A Trial to Evaluate Efficacy of Heart-protecting Musk Pill Unknown status NCT01897805 Phase 4 Heart-protecting Musk Pill;Placebo
10 Effect of Cilostazol on Endothelial Progenitor Cells and Endothelial Function in Coronary Artery Disease Unknown status NCT02174939 Phase 4 Cilostazol;Dummy Placebo
11 The Prediction of Extent and Risk Profile of Coronary Atherosclerosis and Their Changes During Lipid-lowering Therapy Based on Non-invasive Techniques Unknown status NCT01773512 Phase 4 Rosuvastatin
12 The Association Between Very Small Embryonic-like Stem Cells and the Prognosis of Coronary Artery Disease Patients Unknown status NCT01633359 Phase 4 Intensive statin;Routine statin
13 Efficacy and Safety of Different Dose of Tirofiban in Interventional Treatment of Complex Coronary Artery Disease Unknown status NCT02294994 Phase 4 tirofiban
14 Firebird 2 Versus Excel Sirolimus-eluting Stent in Treating Real-world Patients With Coronary Artery Disease Unknown status NCT01373632 Phase 4
15 Pharmacodynamic Comparison of Rosuvastatin Versus Atorvastatin on Platelet Reactivity in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy With New P2Y12 Inhibitors (Trial gRANADa) Unknown status NCT02030054 Phase 4 Atorvastatin;Rosuvastatin
16 Clinical Study of Combination Therapy for Angina of Coronary Heart Disease With Aspirin and Salvianolate Injection Unknown status NCT02694848 Phase 4 Salvianolate injection;Aspirin
17 BioMime Vs. Xience Randomised Control Clinical Study Unknown status NCT02112981 Phase 4
18 Low-dose Statins and Nutraceuticals in High-intensity Statin-intolerant Patients Unknown status NCT02001883 Phase 4 Association low-dose statin and nutraceuticals
19 Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis - SAfety & EffectiveneSS of Drug-ElUting Stents & Anti-platelet REgimen Unknown status NCT01267734 Phase 4 Triple anti-platelet therapy (TAT);Double-dose clopidogrel anti-platelet therapy (DDAT)
20 The ImPact of Trimetazidine on MicrOcirculation After Stenting for Stable Coronary Artery Disease Unknown status NCT02107144 Phase 4 trimetazidine
21 Can Insulin Glargine Improve Myocardial Function in Patients With T2D and Coronary Artery Disease (CAD) Unknown status NCT01035528 Phase 4 insulin glargine;metformin
22 Cerebral Artery Stenosis, Coronary Artery Disease and Arrhythmia Unknown status NCT00247533 Phase 4
23 Xience/Promus for Long Coronary Lesion Registry Unknown status NCT01147237 Phase 4
24 A Prospective Multicenter Trial Evaluating Helios Biodegradable Polymer SES Safety and Effectiveness in CAD Treatment Unknown status NCT01880879 Phase 4
25 Pharmacodynamic Effects of Atorvastatin vs. Rosuvastatin on Platelet Reactivity Unknown status NCT01567774 Phase 4 Atorvastatin;Rosuvastatin
26 Treatment of Coronary Atherosclerosis by Insulin Sensitizers in Insulin-Resistant Patients Unknown status NCT00155350 Phase 4 pioglitazone
27 Impact of Acarbose on Abnormal Glucose Regulation in Patients With Coronary Artery Disease (AAA Trial) Unknown status NCT00858676 Phase 4 acarbose
28 Fluvastatin AmelIorates aTHerosclerosis Study Unknown status NCT01681199 Phase 4 Fluvastatin extended release tablet
29 Pharmacodynamic Effects of Ranolazine Versus Amlodipine on Platelet Reactivity Unknown status NCT01490255 Phase 4 Ranolazine;Amlodipine
30 Ranolazine for Improving Symptoms of Palpitations Unknown status NCT01495520 Phase 4 Ranolazine;Placebo
31 Rivaroxaban in Patients With Atrial Fibrillation and Coronary Artery Disease Undergoing Percutaneous Coronary Intervention Unknown status NCT02334254 Phase 4 rivaroxaban and ticagrel therapy;triple antithrombotic regimen with warfarin, asipirin and clopidogrel
32 Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease Study Unknown status NCT02642419 Phase 4 Rivaroxaban and single antiplatelet drug (aspirin, clopidogrel or prasugrel);Rivaroxaban
33 Safety and Effectiveness of the Coronary Momo Stent Unknown status NCT01535625 Phase 4
34 Study Effects of Ginkgo Biloba Extract on Endothelial Cell Function and Genetic Effects on the Response to Ginkgo Biloba Extract in Diabetic Patients With Stable Coronary Artery Disease Unknown status NCT01038050 Phase 4 Ginkgo Biloba Extract (GBE)
35 Assessment of Surface Coverage of Two Types of DES in Diabetes Mellitus and Non- Diabetes Mellitus Unknown status NCT01023919 Phase 4
36 Overcoming High On-Treatment Platelet Reactivity (HPR) During Prasugrel Therapy With Ticagrelor Unknown status NCT01869309 Phase 4 Prasugrel;Ticagrelor
37 Comparison of Diabetes Mellitus and Non-diabetes Mellitus Patients for DES Surface COVERage by OCT Unknown status NCT01021930 Phase 4
38 PharmacOdynamic compaRison of piTavastatin Versus atOrvastatin on Platelet Reactivity Unknown status NCT01648829 Phase 4 Atorvastatin;Pitavastatin
39 Rosiglitazone Therapy In The Prevention Of Coronary Artery Disease In Patients With Impaired Glucose Tolerance Unknown status NCT00733174 Phase 4 Rosiglitazone;Placebo
40 Multivessel Stenting Versus Staged Revascularization With Zotarolimus-eluting Stent for STEMI Unknown status NCT01781715 Phase 4
41 Cholesterol-lowering Effects of nutraceuticaLs Versus Ezetimibe in Statin-intolerant Patients Unknown status NCT01807078 Phase 4 Ezetimibe
42 Ranolazine, Ethnicity and the Metabolic Syndrome Unknown status NCT01304095 Phase 4 Ranolazine
43 Ischemia In Hemodialysed Patients: Ivabradine Versus Carvedilol Unknown status NCT01425164 Phase 4 Ivabradine;Carvedilol
44 Comparison of Biolimus-eluting Biodegradable Polymer, Everolimus-eluting and Sirolimus-eluting Coronary Stents Unknown status NCT01268371 Phase 4
45 Plasma and Platelet microRNAs in Clopidogrel Low Response Patients Unknown status NCT02447809 Phase 4 Clopidogrel;acetylsalicylic acid (ASA)
46 Periodontal Therapy in Coronary Artery Patients Unknown status NCT01609725 Phase 4
47 A Registry To Evaluate Safety And Effectiveness Of Everolimus Drug Eluting Stent For Coronary Revascularization Unknown status NCT01157455 Phase 4 Aspirin;Clopidogrel;Heparin or Bivalirudin
48 Italian Diffuse/Multivessel Disease ABSORB Prospective Registry: IT-Disappears Unknown status NCT02004730 Phase 4
49 The Effects of Omega 3 and Vitamin E Supplementation on the Serum Antioxidant Enzymes and Gene Expressions of PGC-1a, h TERT, FOXOs and SIRTs in CAD Patients Unknown status NCT02011906 Phase 4
50 Diagnostic Performance of Noninvasive Fractional Flow Reserve From Computed Tomography Unknown status NCT01747317 Phase 4

Search NIH Clinical Center for Coronary Heart Disease 1

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Genetic Tests for Coronary Heart Disease 1

Genetic tests related to Coronary Heart Disease 1:

# Genetic test Affiliating Genes
1 Coronary Heart Disease 1 28 CX3CR1
2 Coronary Heart Disease 28

Anatomical Context for Coronary Heart Disease 1

MalaCards organs/tissues related to Coronary Heart Disease 1:

38
Heart, Liver

Publications for Coronary Heart Disease 1

Articles related to Coronary Heart Disease 1:

(show top 50) (show all 2138)
# Title Authors Year
1
Human cytomegalovirus infection and coronary heart disease: a systematic review. ( 29409508 )
2018
2
PON2 and PPARG polymorphisms as biomarkers of risk for coronary heart disease. ( 29441810 )
2018
3
National Prevalence of Self-Reported Coronary Heart Disease and Chronic Stable Angina Pectoris: Factor Analysis of the Underlying Cardiometabolic Risk Factors in the Fourth Round of the SuRFNCD-2011. ( 29434010 )
2018
4
A study on the relationship between plasma selenium concentration and erythrocyte deformability in rat models of coronary heart disease. ( 29442482 )
2018
5
Fine particulate matter and incident coronary heart disease in the REGARDS cohort. ( 29447790 )
2018
6
Corrigendum to 'Effects of RG7652, a Monoclonal Antibody Against PCSK9, on Low-Density Lipoprotein Cholesterol (LDL-C), LDL-C Subfractions, and Inflammatory Biomarkers in Patients at High Risk of or with Established Coronary Heart Disease (From the Phase 2 EQUATOR Study)' The American Journal of Cardiology 119 (2017) 1576-1583. ( 29448977 )
2018
7
Associations of Vitamin D-Binding Globulin and Bioavailable Vitamin D Concentrations With Coronary Heart Disease Events: The Multi-Ethnic Study of Atherosclerosis (MESA). ( 28472285 )
2017
8
LipoproteinA (a) and coronary heart disease - is there an efficient secondary prevention? ( 28233270 )
2017
9
Association between chemokine CXC ligand 12 gene polymorphism (rs1746048) and coronary heart disease: A MOOSE-compliant meta-analysis. ( 28614256 )
2017
10
Increased Plasma Concentrations of Soluble ST2 Independently Predict Mortality but not Cardiovascular Events in Stable Coronary Heart Disease Patients: 13-Year Follow-up of the KAROLA Study. ( 28283847 )
2017
11
The effect of replacing saturated fat with mostly n-6 polyunsaturated fat on coronary heart disease: a meta-analysis of randomised controlled trials. ( 28526025 )
2017
12
Psychosocial risk factors in relation to other cardiovascular risk factors in coronary heart disease: Results from the EUROASPIRE IV survey. A registry from the European Society of Cardiology. ( 28534422 )
2017
13
PIK3CG single nucleotide polymorphisms are associated with poor responsiveness to clopidogrel and increased risk of ischemia in patients with coronary heart disease. ( 28885323 )
2017
14
Cluster analysis for syndromes of real-world coronary heart disease with angina pectoris. ( 29209917 )
2017
15
Response to the letter to the editor regarding "Smoking and coronary heart disease in patients with type 2 diabetes mellitus". ( 28951340 )
2017
16
Lipoprotein-associated phospholipase A2, and subsequent cardiovascular events and mortality among patients with coronary heart disease. ( 27097870 )
2017
17
Growth Differentiation Factor 15 Predicts All-Cause Morbidity and Mortality in Stable Coronary Heart Disease. ( 27811204 )
2017
18
Protein-Truncating Variants at the Cholesteryl Ester Transfer Protein Gene and Risk for Coronary Heart Disease. ( 28506971 )
2017
19
Genetic Variation at the Sulfonylurea Receptor, Type 2 Diabetes, and Coronary Heart Disease. ( 28411266 )
2017
20
Associations of tissue transglutaminase antibody seropositivity with coronary heart disease: Findings from a prospective cohort study. ( 28756971 )
2017
21
Influence of SCARB1 gene SNPs on serum lipid levels and susceptibility to coronary heart disease and cerebral infarction in a Chinese population. ( 28552715 )
2017
22
Circulating fibroblast activation protein activity and antigen levels correlate strongly when measured in liver disease and coronary heart disease. ( 28582421 )
2017
23
Association between hemorrhoid and risk of coronary heart disease: A nationwide population-based cohort study. ( 28767586 )
2017
24
Carotid atherosclerosis and its relationship to coronary heart disease and stroke risk in patients with type 2 diabetes mellitus. ( 28953658 )
2017
25
Association between Toll-like receptor 4 Asp299Gly polymorphism and coronary heart disease susceptibility. ( 28793055 )
2017
26
The potential role of mitochondrial ATP synthase inhibitory factor 1 (IF1) in coronary heart disease: a literature review. ( 28173810 )
2017
27
Predictive Effects of Circulating miR-221, miR-130a and miR-155 for Coronary Heart Disease: A Multi-Ethnic Study in China. ( 28628920 )
2017
28
Association between PPAP2B gene polymorphisms and coronary heart disease susceptibility in Chinese Han males and females. ( 28061459 )
2017
29
Glutathione S-Transferase T1 (GSTT1) Null Polymorphism, Smoking, and Their Interaction in Coronary Heart Disease: A Comprehensive Meta-Analysis. ( 27686690 )
2017
30
Association between Lp-PLA2 and coronary heart disease in Chinese patients. ( 28222638 )
2017
31
The Association between the C5263T Mutation in the Mitochondrial ND2 Gene and Coronary Heart Disease among Young Chinese Han People. ( 28494837 )
2017
32
Smoking and coronary heart disease in patients with type 2 diabetes mellitus. ( 28951339 )
2017
33
Lipoprotein-associated phospholipase A2 in coronary heart disease: Review and meta-analysis. ( 27956130 )
2017
34
Long term gluten consumption in adults without celiac disease and risk of coronary heart disease: prospective cohort study. ( 28465308 )
2017
35
Elevated ambulatory systolic-diastolic pressure regression index is genetically determined in hypertensive patients with coronary heart disease. ( 28092973 )
2017
36
Paraoxonase 1 (Q192R) gene polymorphism, coronary heart disease and the risk of a new acute coronary event. ( 27863895 )
2017
37
Decreased frequencies and impaired functions of the CD31(+) subpopulation in Treg cells associated with decreased FoxP3 expression and enhanced Treg cell defects in patients with coronary heart disease. ( 27997991 )
2017
38
Diabetes mellitus is a coronary heart disease risk equivalent for peripheral vascular disease. ( 28224925 )
2017
39
Hyperuricemia does not seem to be an independent risk factor for coronary heart disease. ( 28917080 )
2017
40
Polymorphisms of CYP2C8, CYP2C9 and CYP2C19 and risk of coronary heart disease in Russian population. ( 28687336 )
2017
41
[Association of ITGB3, P2RY12, and CYP2C19 gene polymorphisms with platelet functional activity in patients with coronary heart disease during dual antiplatelet therapy]. ( 28631703 )
2017
42
Adipokine and Cytokine Profiles of Epicardial and Subcutaneous Adipose Tissue in Patients with Coronary Heart Disease. ( 28948552 )
2017
43
OS 22-04 Impact of Hemorrhoid on Coronary Heart Disease Development with or without Concomitant Comorbidities: A Population Based Cohort Study. ( 27643033 )
2016
44
Association of N-acetyltransferase-2 polymorphism with an increased risk of coronary heart disease in a Chinese population. ( 26985933 )
2016
45
Serum levels and clinical significance of IFN-I^ and IL-10 in patients with coronary heart disease. ( 27097956 )
2016
46
Single nucleotide polymorphism rs3774261 in the AdipoQ gene is associated with the risk of coronary heart disease (CHD) in Northeast Han Chinese population: a case-control study. ( 26754433 )
2016
47
Genomic prediction of coronary heart disease. ( 27655226 )
2016
48
Serum sex hormone and growth arrest-specific protein 6 levels in male patients with coronary heart disease. ( 26924277 )
2016
49
The interplay between genetics, epigenetics and environment in modulating the risk of coronary heart disease. ( 28090516 )
2016
50
Genetic polymorphisms of eNOS (-786T/C, Intron 4b/4a & 894G/T) and its association with asymptomatic first degree relatives of coronary heart disease patients. ( 27613099 )
2016

Variations for Coronary Heart Disease 1

ClinVar genetic disease variations for Coronary Heart Disease 1:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 APOC3 NM_000040.2(APOC3): c.55C> T (p.Arg19Ter) single nucleotide variant Pathogenic,protective rs76353203 GRCh37 Chromosome 11, 116701353: 116701353
2 APOC3 NM_000040.2(APOC3): c.55+1G> A single nucleotide variant Pathogenic,protective rs138326449 GRCh38 Chromosome 11, 116830638: 116830638
3 APOC3 NM_000040.2(APOC3): c.127G> A (p.Ala43Thr) single nucleotide variant Pathogenic,protective rs147210663 GRCh38 Chromosome 11, 116830844: 116830844
4 APOC3 NM_000040.2(APOC3): c.179+1G> T single nucleotide variant Pathogenic,protective rs140621530 GRCh38 Chromosome 11, 116830897: 116830897
5 LPL NM_000237.2(LPL): c.106G> A (p.Asp36Asn) single nucleotide variant risk factor rs1801177 GRCh37 Chromosome 8, 19805708: 19805708

Expression for Coronary Heart Disease 1

Search GEO for disease gene expression data for Coronary Heart Disease 1.

Pathways for Coronary Heart Disease 1

Pathways related to Coronary Heart Disease 1 according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.37 APOA1 APOB APOC3 APOE LPL
2
Show member pathways
11.99 APOA1 APOB APOE CRP INS
3
Show member pathways
11.97 APOA1 APOB APOC3 APOE CETP LPL
4
Show member pathways
11.88 APOA1 APOB APOC3 APOE LPL
5
Show member pathways
11.65 APOA1 APOB APOE
6 11.47 HMGCR INS LPL
7 11.44 APOA1 APOC3 LPL
8
Show member pathways
11.24 APOA1 APOB APOC3 APOE CETP HMGCR
9 11 ACE APOE CX3CR1

GO Terms for Coronary Heart Disease 1

Cellular components related to Coronary Heart Disease 1 according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 early endosome GO:0005769 9.85 ADRB1 APOA1 APOB APOC3 APOE
2 endoplasmic reticulum lumen GO:0005788 9.81 APOA1 APOB APOE INS
3 endocytic vesicle lumen GO:0071682 9.58 APOA1 APOB APOE
4 high-density lipoprotein particle GO:0034364 9.56 APOA1 APOE CETP PON1
5 low-density lipoprotein particle GO:0034362 9.54 APOA1 APOB APOE
6 endosome lumen GO:0031904 9.52 APOB INS
7 spherical high-density lipoprotein particle GO:0034366 9.5 APOA1 APOC3 PON1
8 discoidal high-density lipoprotein particle GO:0034365 9.48 APOA1 APOE
9 intermediate-density lipoprotein particle GO:0034363 9.46 APOA1 APOB APOC3 APOE
10 very-low-density lipoprotein particle GO:0034361 9.35 APOA1 APOB APOC3 APOE LPL
11 chylomicron GO:0042627 9.02 APOA1 APOB APOC3 APOE LPL
12 extracellular region GO:0005576 10.19 ACE APOA1 APOB APOC3 APOE CETP
13 extracellular space GO:0005615 10.13 ACE APOA1 APOB APOC3 APOE CETP

Biological processes related to Coronary Heart Disease 1 according to GeneCards Suite gene sharing:

(show all 45)
# Name GO ID Score Top Affiliating Genes
1 lipid transport GO:0006869 9.99 APOA1 APOB APOC3 APOE CETP
2 steroid metabolic process GO:0008202 9.97 APOA1 APOB APOE CETP HMGCR
3 cellular protein metabolic process GO:0044267 9.96 APOA1 APOB APOE INS
4 lipid catabolic process GO:0016042 9.87 APOB APOC3 LPL
5 triglyceride metabolic process GO:0006641 9.86 APOC3 APOE CETP LPL
6 retinoid metabolic process GO:0001523 9.85 APOA1 APOB APOC3 APOE LPL
7 lipoprotein metabolic process GO:0042157 9.8 APOA1 APOB APOC3 APOE
8 cholesterol metabolic process GO:0008203 9.8 APOA1 APOB APOE CETP HMGCR PON1
9 cholesterol transport GO:0030301 9.79 APOA1 APOB CETP
10 low-density lipoprotein particle remodeling GO:0034374 9.78 APOB APOE CETP
11 cholesterol efflux GO:0033344 9.78 APOA1 APOB APOC3 APOE
12 phospholipid efflux GO:0033700 9.77 APOA1 APOC3 APOE
13 negative regulation of blood vessel diameter GO:0097756 9.76 CRP HMGCR INS
14 chylomicron remnant clearance GO:0034382 9.75 APOB APOC3 APOE
15 reverse cholesterol transport GO:0043691 9.73 APOA1 APOC3 APOE CETP
16 regulation of Cdc42 protein signal transduction GO:0032489 9.72 APOA1 APOC3 APOE
17 very-low-density lipoprotein particle remodeling GO:0034372 9.71 APOE CETP LPL
18 high-density lipoprotein particle remodeling GO:0034375 9.71 APOA1 APOC3 APOE CETP
19 lipoprotein biosynthetic process GO:0042158 9.7 APOA1 APOB APOE
20 positive regulation of nitric-oxide synthase activity GO:0051000 9.69 APOE INS
21 negative regulation of lipid catabolic process GO:0050995 9.69 APOC3 INS
22 positive regulation of macrophage derived foam cell differentiation GO:0010744 9.69 APOB LPL
23 positive regulation of cholesterol efflux GO:0010875 9.68 APOE PON1
24 negative regulation of macrophage derived foam cell differentiation GO:0010745 9.68 CETP CRP
25 high-density lipoprotein particle assembly GO:0034380 9.68 APOA1 APOE
26 fatty acid homeostasis GO:0055089 9.68 APOE INS
27 phosphatidylcholine metabolic process GO:0046470 9.67 CETP PON1
28 positive regulation of lipid biosynthetic process GO:0046889 9.67 APOE INS
29 very-low-density lipoprotein particle assembly GO:0034379 9.67 APOB APOC3
30 chylomicron assembly GO:0034378 9.67 APOA1 APOB APOC3 APOE
31 phospholipid homeostasis GO:0055091 9.66 APOA1 CETP
32 positive regulation of cholesterol esterification GO:0010873 9.65 APOA1 APOE
33 high-density lipoprotein particle clearance GO:0034384 9.65 APOA1 APOE
34 negative regulation of long-term synaptic potentiation GO:1900272 9.65 APOE CX3CR1
35 triglyceride homeostasis GO:0070328 9.65 APOA1 APOC3 APOE CETP LPL
36 neuron projection regeneration GO:0031102 9.64 APOA1 APOE
37 positive regulation of cholesterol storage GO:0010886 9.64 APOB LPL
38 very-low-density lipoprotein particle clearance GO:0034447 9.63 APOB APOE
39 positive regulation of dendritic spine maintenance GO:1902952 9.63 APOE INS
40 cholesterol homeostasis GO:0042632 9.63 APOA1 APOB APOC3 APOE CETP LPL
41 lipoprotein catabolic process GO:0042159 9.62 APOB APOE
42 negative regulation of very-low-density lipoprotein particle remodeling GO:0010903 9.62 APOA1 APOC3
43 triglyceride catabolic process GO:0019433 9.35 APOA1 APOB APOC3 APOE LPL
44 chylomicron remodeling GO:0034371 9.02 APOA1 APOB APOC3 APOE LPL
45 lipid metabolic process GO:0006629 10.11 APOA1 APOB APOC3 APOE CETP HMGCR

Molecular functions related to Coronary Heart Disease 1 according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 lipid binding GO:0008289 9.83 APOA1 APOB APOC3 APOE CETP
2 cholesterol binding GO:0015485 9.56 APOA1 APOC3 APOE CETP
3 phospholipid binding GO:0005543 9.55 APOA1 APOB APOC3 APOE PON1
4 phospholipid transporter activity GO:0005548 9.51 APOA1 CETP
5 low-density lipoprotein particle receptor binding GO:0050750 9.5 APOB APOE CRP
6 lipase inhibitor activity GO:0055102 9.49 APOA1 APOC3
7 lipoprotein particle binding GO:0071813 9.48 APOA1 APOE
8 phosphatidylcholine-sterol O-acyltransferase activator activity GO:0060228 9.46 APOA1 APOE
9 high-density lipoprotein particle receptor binding GO:0070653 9.4 APOA1 APOC3
10 triglyceride binding GO:0017129 9.37 CETP LPL
11 lipid transporter activity GO:0005319 9.26 APOA1 APOB APOE CETP
12 cholesterol transporter activity GO:0017127 8.92 APOA1 APOB APOE CETP

Sources for Coronary Heart Disease 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....